Salmon SE, Hamburger AW, Soehnlen B. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 1978;298:1321–1327.
Bertelsen CA, Sondak VK, Mann BD. Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations. Cancer 1984;53:1240–1245.
Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 1990;2:582–588.
Alberts DS, Samon S.E, Chen HS. In-vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet 1980;2:340–342.
Von Hoff DD, Kronmal R, Salmon SE. A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. Cancer 1991;67:20–27.
Kurbacher CM, Cree IA, Bruckner HW. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs 1998;9:51–57.
Maenpaa JU, Heinonen E, Hinkka SM. The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial. Gynecol Oncol 1995;57:294–298.
Loizzi V, Chan JK, Osann K. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 2003;189:1301–1307.
Holloway RW, Mehta RS, Finkler NJ. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 2002;87:8–16.
Nagourney RA, Brewer CA, Radecki S. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 2003;88:35–39.
Gallion H, Christopherson WA, Coleman RL. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 2006;16:194–201.
Schrag D, Garewal HS, Burstein HJ. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 2004;22:3631–3638.
Samson DJ, Seidenfeld J, Ziegler K, Aronson N. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 2004;22:3618–3630.
Eltabbakh GH. Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma. J Surg Oncol 2000;73:148–152.
Eltabbakh GH, Piver MS, Hempling RE. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecol Oncol 1998;70:392–397.
Karam AK, Chiang JW, Fung E. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. Gynecol Oncol 2009;114:246–252.
Warren JL, Yabroff KR, Meekins A. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 2008;100:888–897.